Diagnostic Performance of Dobutamine Stress Echocardiography in End-Stage Liver Disease

Anisiia T. Doytchinova, Thomas D. Feigenbaum, Roja C. Pondicherry-Harish, Peter Sepanski, Deborah Green-Hess, Harvey Feigenbaum, Stephen G. Sawada

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Objectives: This study determined the test performance of dobutamine stress echocardiography (DSE) in end-stage liver disease (ESLD). Background: The reported sensitivity of DSE in ESLD has been variable. Methods: Data from 633 ESLD patients who had coronary angiography within 6 months after DSE was analyzed. Results: The prevalence of coronary arterial disease (CAD) (≥70% stenosis by quantitative angiography) was 12% (74 of 633 patients). DSE sensitivity was 24% (17 of 72 patients), and specificity was 90% (503 of 559 patients). The positive and negative predictive values were 23% (17 of 73 patients) and 90% (503 of 558 patients), respectively. Stratifying the cohort into low-, intermediate-, and high-risk CAD groups yielded sensitivities of 0%, 21%, and 32%, respectively. Independent predictors of an accurate ischemic DSE result included left ventricular internal dimension at end-diastole (LVIDd) >4.8 cm and assigning ischemia based on tardokinesis or lack of low-to-peak dose hyperkinesis (p < 0.05 for all). DSE sensitivity was 38% in LVIDd >4.8 cm versus 13% with LVIDd ≤4.8 cm (p = 0.013). The sensitivity was 67% when tardokinesis or lack of hyperkinesis was considered abnormal versus 15% (p < 0.001) for readings that did not consider tardokinesis or lack of hyperkinesis abnormal. There was a higher frequency of cardiac events in patients with significant CAD who had abnormal (45%) versus normal (18%) DSE (p = 0.01). Conclusions: The sensitivity of DSE in ESLD was low. DSE sensitivity was higher for those with larger cavity dimension and when tardokinesis or lack of hyperkinesis was considered abnormal. An abnormal DSE in those with significant CAD was associated with worse outcome.

Original languageEnglish (US)
Pages (from-to)2115-2122
Number of pages8
JournalJACC: Cardiovascular Imaging
Volume12
Issue number11P1
DOIs
StatePublished - Nov 2019

Fingerprint

Stress Echocardiography
End Stage Liver Disease
Hyperkinesis
Coronary Disease
Diastole
Coronary Angiography
Reading
Angiography
Pathologic Constriction
Ischemia

Keywords

  • dobutamine stress echocardiogram
  • end-stage liver disease
  • left ventricular internal dimension at end-diastole
  • rate−pressure product
  • sensitivity
  • tardokinesis

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Cardiology and Cardiovascular Medicine

Cite this

Doytchinova, A. T., Feigenbaum, T. D., Pondicherry-Harish, R. C., Sepanski, P., Green-Hess, D., Feigenbaum, H., & Sawada, S. G. (2019). Diagnostic Performance of Dobutamine Stress Echocardiography in End-Stage Liver Disease. JACC: Cardiovascular Imaging, 12(11P1), 2115-2122. https://doi.org/10.1016/j.jcmg.2018.10.031

Diagnostic Performance of Dobutamine Stress Echocardiography in End-Stage Liver Disease. / Doytchinova, Anisiia T.; Feigenbaum, Thomas D.; Pondicherry-Harish, Roja C.; Sepanski, Peter; Green-Hess, Deborah; Feigenbaum, Harvey; Sawada, Stephen G.

In: JACC: Cardiovascular Imaging, Vol. 12, No. 11P1, 11.2019, p. 2115-2122.

Research output: Contribution to journalArticle

Doytchinova, AT, Feigenbaum, TD, Pondicherry-Harish, RC, Sepanski, P, Green-Hess, D, Feigenbaum, H & Sawada, SG 2019, 'Diagnostic Performance of Dobutamine Stress Echocardiography in End-Stage Liver Disease', JACC: Cardiovascular Imaging, vol. 12, no. 11P1, pp. 2115-2122. https://doi.org/10.1016/j.jcmg.2018.10.031
Doytchinova AT, Feigenbaum TD, Pondicherry-Harish RC, Sepanski P, Green-Hess D, Feigenbaum H et al. Diagnostic Performance of Dobutamine Stress Echocardiography in End-Stage Liver Disease. JACC: Cardiovascular Imaging. 2019 Nov;12(11P1):2115-2122. https://doi.org/10.1016/j.jcmg.2018.10.031
Doytchinova, Anisiia T. ; Feigenbaum, Thomas D. ; Pondicherry-Harish, Roja C. ; Sepanski, Peter ; Green-Hess, Deborah ; Feigenbaum, Harvey ; Sawada, Stephen G. / Diagnostic Performance of Dobutamine Stress Echocardiography in End-Stage Liver Disease. In: JACC: Cardiovascular Imaging. 2019 ; Vol. 12, No. 11P1. pp. 2115-2122.
@article{8c7277a407484ef7ab20e7c4597edc55,
title = "Diagnostic Performance of Dobutamine Stress Echocardiography in End-Stage Liver Disease",
abstract = "Objectives: This study determined the test performance of dobutamine stress echocardiography (DSE) in end-stage liver disease (ESLD). Background: The reported sensitivity of DSE in ESLD has been variable. Methods: Data from 633 ESLD patients who had coronary angiography within 6 months after DSE was analyzed. Results: The prevalence of coronary arterial disease (CAD) (≥70{\%} stenosis by quantitative angiography) was 12{\%} (74 of 633 patients). DSE sensitivity was 24{\%} (17 of 72 patients), and specificity was 90{\%} (503 of 559 patients). The positive and negative predictive values were 23{\%} (17 of 73 patients) and 90{\%} (503 of 558 patients), respectively. Stratifying the cohort into low-, intermediate-, and high-risk CAD groups yielded sensitivities of 0{\%}, 21{\%}, and 32{\%}, respectively. Independent predictors of an accurate ischemic DSE result included left ventricular internal dimension at end-diastole (LVIDd) >4.8 cm and assigning ischemia based on tardokinesis or lack of low-to-peak dose hyperkinesis (p < 0.05 for all). DSE sensitivity was 38{\%} in LVIDd >4.8 cm versus 13{\%} with LVIDd ≤4.8 cm (p = 0.013). The sensitivity was 67{\%} when tardokinesis or lack of hyperkinesis was considered abnormal versus 15{\%} (p < 0.001) for readings that did not consider tardokinesis or lack of hyperkinesis abnormal. There was a higher frequency of cardiac events in patients with significant CAD who had abnormal (45{\%}) versus normal (18{\%}) DSE (p = 0.01). Conclusions: The sensitivity of DSE in ESLD was low. DSE sensitivity was higher for those with larger cavity dimension and when tardokinesis or lack of hyperkinesis was considered abnormal. An abnormal DSE in those with significant CAD was associated with worse outcome.",
keywords = "dobutamine stress echocardiogram, end-stage liver disease, left ventricular internal dimension at end-diastole, rate−pressure product, sensitivity, tardokinesis",
author = "Doytchinova, {Anisiia T.} and Feigenbaum, {Thomas D.} and Pondicherry-Harish, {Roja C.} and Peter Sepanski and Deborah Green-Hess and Harvey Feigenbaum and Sawada, {Stephen G.}",
year = "2019",
month = "11",
doi = "10.1016/j.jcmg.2018.10.031",
language = "English (US)",
volume = "12",
pages = "2115--2122",
journal = "JACC: Cardiovascular Imaging",
issn = "1936-878X",
publisher = "Elsevier Inc.",
number = "11P1",

}

TY - JOUR

T1 - Diagnostic Performance of Dobutamine Stress Echocardiography in End-Stage Liver Disease

AU - Doytchinova, Anisiia T.

AU - Feigenbaum, Thomas D.

AU - Pondicherry-Harish, Roja C.

AU - Sepanski, Peter

AU - Green-Hess, Deborah

AU - Feigenbaum, Harvey

AU - Sawada, Stephen G.

PY - 2019/11

Y1 - 2019/11

N2 - Objectives: This study determined the test performance of dobutamine stress echocardiography (DSE) in end-stage liver disease (ESLD). Background: The reported sensitivity of DSE in ESLD has been variable. Methods: Data from 633 ESLD patients who had coronary angiography within 6 months after DSE was analyzed. Results: The prevalence of coronary arterial disease (CAD) (≥70% stenosis by quantitative angiography) was 12% (74 of 633 patients). DSE sensitivity was 24% (17 of 72 patients), and specificity was 90% (503 of 559 patients). The positive and negative predictive values were 23% (17 of 73 patients) and 90% (503 of 558 patients), respectively. Stratifying the cohort into low-, intermediate-, and high-risk CAD groups yielded sensitivities of 0%, 21%, and 32%, respectively. Independent predictors of an accurate ischemic DSE result included left ventricular internal dimension at end-diastole (LVIDd) >4.8 cm and assigning ischemia based on tardokinesis or lack of low-to-peak dose hyperkinesis (p < 0.05 for all). DSE sensitivity was 38% in LVIDd >4.8 cm versus 13% with LVIDd ≤4.8 cm (p = 0.013). The sensitivity was 67% when tardokinesis or lack of hyperkinesis was considered abnormal versus 15% (p < 0.001) for readings that did not consider tardokinesis or lack of hyperkinesis abnormal. There was a higher frequency of cardiac events in patients with significant CAD who had abnormal (45%) versus normal (18%) DSE (p = 0.01). Conclusions: The sensitivity of DSE in ESLD was low. DSE sensitivity was higher for those with larger cavity dimension and when tardokinesis or lack of hyperkinesis was considered abnormal. An abnormal DSE in those with significant CAD was associated with worse outcome.

AB - Objectives: This study determined the test performance of dobutamine stress echocardiography (DSE) in end-stage liver disease (ESLD). Background: The reported sensitivity of DSE in ESLD has been variable. Methods: Data from 633 ESLD patients who had coronary angiography within 6 months after DSE was analyzed. Results: The prevalence of coronary arterial disease (CAD) (≥70% stenosis by quantitative angiography) was 12% (74 of 633 patients). DSE sensitivity was 24% (17 of 72 patients), and specificity was 90% (503 of 559 patients). The positive and negative predictive values were 23% (17 of 73 patients) and 90% (503 of 558 patients), respectively. Stratifying the cohort into low-, intermediate-, and high-risk CAD groups yielded sensitivities of 0%, 21%, and 32%, respectively. Independent predictors of an accurate ischemic DSE result included left ventricular internal dimension at end-diastole (LVIDd) >4.8 cm and assigning ischemia based on tardokinesis or lack of low-to-peak dose hyperkinesis (p < 0.05 for all). DSE sensitivity was 38% in LVIDd >4.8 cm versus 13% with LVIDd ≤4.8 cm (p = 0.013). The sensitivity was 67% when tardokinesis or lack of hyperkinesis was considered abnormal versus 15% (p < 0.001) for readings that did not consider tardokinesis or lack of hyperkinesis abnormal. There was a higher frequency of cardiac events in patients with significant CAD who had abnormal (45%) versus normal (18%) DSE (p = 0.01). Conclusions: The sensitivity of DSE in ESLD was low. DSE sensitivity was higher for those with larger cavity dimension and when tardokinesis or lack of hyperkinesis was considered abnormal. An abnormal DSE in those with significant CAD was associated with worse outcome.

KW - dobutamine stress echocardiogram

KW - end-stage liver disease

KW - left ventricular internal dimension at end-diastole

KW - rate−pressure product

KW - sensitivity

KW - tardokinesis

UR - http://www.scopus.com/inward/record.url?scp=85073945908&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85073945908&partnerID=8YFLogxK

U2 - 10.1016/j.jcmg.2018.10.031

DO - 10.1016/j.jcmg.2018.10.031

M3 - Article

C2 - 30660519

AN - SCOPUS:85073945908

VL - 12

SP - 2115

EP - 2122

JO - JACC: Cardiovascular Imaging

JF - JACC: Cardiovascular Imaging

SN - 1936-878X

IS - 11P1

ER -